在遗传性血小板疾病中的静脉血栓栓塞:临床挑战
Francesco Paciullo1, Patrizia Rovere-Querini1,2, Loredana Bury3
1Faculty of Medicine and Surgery, Vita-Salute San Raffaele University, 20132 Milan, Italy.
Diagnostics (Basel, Switzerland)
|November 13, 2025
概括
遗传性血小板疾病 (IPD) 增加了静脉血栓塞栓症 (VTE) 的风险,尽管明显风险较低. 在IPD患者中管理VTE是具有挑战性的,因为有出血和凝血问题,特别是在手术期间.
科学领域:
- 血液学 血液学 血液学
- 血栓形成和血液静止.
背景情况:
- 遗传性血小板疾病 (IPD) 是一种影响血小板数量或功能的罕见疾病.
- 患有IPD的患者具有具有矛盾的静脉血栓塞栓症 (VTE) 的风险,这是一个重要的死亡原因.
- 由于平衡出血和凝血风险,IPD患者的静脉瘤治疗是复杂的.
研究的目的:
- 审查IPD患者中VTE的发病率和风险因素.
- 为IPD患者概述VTE管理策略.
- 专注于在IPD中围绕手术的VTE考虑.
主要方法:
- 对当前证据的文献综述.
- 综合有关VTE发病率和IPD风险因素的数据.
- 分析VTE治疗和预防策略.
主要成果:
- 在IPD患者中,尽管发病率似乎较低,但VTE是持续存在的风险.
- 在这个人群中确定VTE的特定风险因素至关重要.
- 术后管理需要仔细考虑抗血栓治疗.
结论:
- 在IPD患者中,VTE具有显著的,尽管复杂的风险.
- 有效的VTE预防和治疗策略是必不可少的,特别是在手术环境中.
- 需要进行进一步的研究,以优化对IPD患者的VTE护理.
相关概念视频
Disorders of Hemostasis
2.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.0K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Venous Thrombosis I: Introduction
334
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
334
Venous Thrombosis III: Interprofessional Care
271
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
271
Venous Thrombosis IV: Nursing Management
190
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
190
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K


